Premium
CA 19‐9 and pancreatic adenocarcinoma
Author(s) -
Safi Farouk,
Beger Hans G.,
Bittner Reinhard,
Büchler Markus,
Krautzberger Wolfgang
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19860215)57:4<779::aid-cncr2820570417>3.0.co;2-c
Subject(s) - medicine , gastroenterology , pancreatitis , adenocarcinoma , carcinoma , pancreatic carcinoma , pancreas , pancreatic disease , pancreatic cancer , cancer
The diagnostic place value of CA 19‐9, a tumor‐associated antigen, was tested in 611 patients. This group of patients included 273 patients who suffered from a malignant disease (48 patients with pancreatic carcinomas and 225 patients with extrapancreatic malignant growths) and 338 patients with benign diseases (66 patients with chronic pancreatitis, 36 patients with acute pancreatitis, and 236 patients with general surgical diseases). In 93% of the patients with pancreatic carcinoma (median value, 528 U/ml), in 37% and 19% of the patients with carcinoma of the stomach and colorectal carcinomas (median value 8 U/ml), respectively, the CA 19‐9 value was estimated as being above the normal limits of 6 to 37 U/ml. A sensitivity of 93% and a specificity of 85%, as well as a total accuracy of 82%, were established in pancreatic carcinoma during preoperative observation. The preoperatively raised CA 19‐9 concentration in patients with pancreatic carcinomas dropped after curative resection of the carcinoma to within normal limits. However, a serum concentration of less than 37 U/ml was not recorded in any CA 19‐9 estimation after a palliative surgical intervention, or in any case of inoperable carcinomas.